Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00777790 · ClinicalTrials.gov registry record · Phase 2
Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents
A Phase 2 study, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 241
- Enrollment target
NCT00777790 is a Phase 2 study that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 241 participants.
The verdict
NCT00777790, a Phase 2 study, has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 241 participants
- Enrollment target
Study Summary
This study was designed to evaluate the antibody response to a Menactra® booster dose in participants who previously received one dose of Menactra® or Menomune® as adolescents 3 years earlier in Study MTA02. Primary Objective: To evaluate the antibody responses to a booster dose of a tetravalent meningococcal diphtheria toxoid conjugate vaccine (Menactra®) in participants who had previously received Menactra® or Menomune® as adolescents in the MTA02 Study and antibody responses to a dose of Menactra® in naive adolescents.
Interventions
- BIOLOGICAL Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 241 participants |
| Start Date | 2004-02 |
| Est. Completion | 2005-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00777790
The ClinicalTrials.gov registry entry for NCT00777790 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 241 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Meningococcal Polysaccharide Diphtheria Toxoid Conjugate is the first listed.
NCT00777790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00777790 about?
NCT00777790 is a clinical study titled "Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents". This study was designed to evaluate the antibody response to a Menactra® booster dose in participants who previously received one dose of Menactra® or Menomune® as adolescents 3 years earlier in Study MTA02. Primary Objective: To evaluate the antibody responses to a booster dose of a tetravalent m...
What is the current status of trial NCT00777790?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 241 participants. The study started on 2004-02. Estimated completion is 2005-04.
What interventions are being tested in trial NCT00777790?
The interventions under investigation include: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate (BIOLOGICAL).
Who is sponsoring clinical trial NCT00777790?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.